Blood Based Biomarkers For Neurodegeneration is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Blood-based biomarkers have revolutionized the diagnosis and monitoring of neurodegenerative diseases, transforming what was once reliant on expensive PET imaging or invasive cerebrospinal fluid (CSF) collection into accessible, scalable clinical tools. [1]
The development of ultrasensitive immunoassay platforms—including single-molecule array (Simoa), Meso Scale Discovery (MSD) electrochemiluminescence, and Lumipulse chemiluminescent enzyme immunoassay—has enabled reliable detection of brain-derived proteins in peripheral blood at femtomolar concentrations[2] [3]
. [4]
The core panel of blood biomarkers for neurodegeneration includes phosphorylated tau (p-tau species (p-tau181, p-tau217, p-tau231), Neurofilament light chain (NfL))))))))))))))))))))))))))))))), glial fibrillary acidic protein (GFAP), and Amyloid-Beta ratios (Aβ42/40). These analytes reflect distinct pathological processes: amyloid plaque deposition, tau pathology], neuronal injury, and astrocytic reactivity. [5]
In May 2025, the FDA cleared the first blood test for Alzheimer's disease diagnosis—the Lumipulse G pTau217/β-Amyloid 1-42 Plasma Ratio—marking a landmark clinical milestone[1:1]. [6]
Blood biomarkers are now being integrated into updated diagnostic criteria for AD and are under active investigation for Parkinson's disease, amyotrophic lateral sclerosis, frontotemporal dementia, Huntington's disease, and other neurodegenerative conditions. [7]
Blood-based biomarkers offer significant advantages over traditional imaging and cerebrospinal fluid approaches:
| Characteristic | Blood Biomarkers | CSF Biomarkers | PET Imaging |
|---|---|---|---|
| Invasiveness | Minimal (blood draw) | High (lumbar puncture) | None |
| Cost | $200-500 | $300-600 | $3,000-5,000 |
| Accessibility | Widely available | Specialty labs | Limited centers |
| Time to result | Days | Days-Weeks | Days-Weeks |
| Repeatability | Excellent | Good | Limited |
| Amyloid detection | Good (p-tau217 Aβ42/40) | Excellent | Excellent |
| Tau detection | Good (p-tau217/181) | Excellent | Excellent |
| Neurodegeneration | Good (NfL) | Good | Moderate |
Key advantages of blood biomarkers:
Limitations compared to imaging:
The FDA clearance of the Lumipulse G pTau217 test in May 2025 represents a paradigm shift, validating blood-based biomarkers as equivalent to PET imaging for diagnostic confirmation in Alzheimer's disease.
Blood biomarkers are transforming clinical trial design and patient selection:
For patients being considered for lecanemab or donanemab:
Phosphorylated tau (p-tau biomarkers are highly specific for Alzheimer's Disease pathology and reflect active tau hyperphosphorylation] and secretion from neurons: [8]
P-tau217 has emerged as the most accurate single blood biomarker for AD diagnosis: [9]
Neurofilament light chain (NfL))))))))))))))))))))))))))))))) is a structural cytoskeletal protein released into the extracellular space upon neuronal damage or degeneration: [9:1]
GFAP is an intermediate filament protein primarily expressed by astrocytes and released into the bloodstream during reactive astrogliosis: [13]
Blood biomarkers are reshaping AD diagnostic paradigms: [18]
Blood biomarker panels help distinguish between neurodegenerative conditions: [19]
| Biomarker | AD | FTD | PD | ALS | DLB | [20]
|-----------|-----|-----|-----|-----|-----| [21]
| P-tau217 | ↑↑↑ | Normal | Normal | Normal | ↑ | [22]
| NfL | ↑ | ↑↑ | Normal/↑ | ↑↑↑ | ↑ | [23]
| GFAP | ↑↑ | ↑ | Normal | ↑ | ↑ | [24]
| Aβ42/40 | ↓↓ | Normal | Normal | Normal | ↓ | [25]
Recent 2026 studies reinforce that blood-based biomarkers integrate metabolic, vascular, and proteomic signals that improve early Alzheimer's Disease stratification when interpreted in clinical context.
The study of Blood Based Biomarkers For Neurodegeneration has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
This section highlights recent publications relevant to this mechanism.
'Blood-based biomarkers for Alzheimer''s disease: Advances in early detection and monitoring of age-related neurodegeneration'. ↩︎ ↩︎ ↩︎ ↩︎
The association between temporal-lobe tensor-based morphometry and plasma amyloid-β in mild cognitive impairment. ↩︎ ↩︎ ↩︎ ↩︎
Profiling mitochondrial DNA indices across whole blood, plasma, and CSF in amyotrophic lateral sclerosis. ↩︎ ↩︎ ↩︎
'Association between sleep duration and fluid biomarkers of Alzheimer''s disease: A systematic review'. ↩︎ ↩︎ ↩︎ ↩︎
A physically and mentally active lifestyle relates to younger brain and cognitive age. ↩︎ ↩︎ ↩︎
:. Parra et al., Blood-based AT(N) biomarkers for Alzheimer's Disease and frontotemporal lobar degeneration in Latin America (2026). 2026. ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
Aisen et al. Concurrent Changes in Plasma Phosphorylated Tau 217, Tau PET, and Cognition in Preclinical Alzheimer's Disease (2025). 2025. ↩︎ ↩︎ ↩︎ ↩︎
Aisen et al. Multimodal prognostic modeling of individual cognitive trajectories to enhance trial efficiency in preclinical Alzheimer's Disease (2025). 2025. ↩︎ ↩︎ ↩︎
Petersen et al. Predicting onset of symptomatic Alzheimer's Disease with plasma p-tau217 clocks (2026). 2026. ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
Arslan et al. 'Comparative analysis of plasma p-tau217 immunoassays: challenges for standardization and harmonization (2026)'. 2026. ↩︎ ↩︎ ↩︎ ↩︎
Titeca et al. Automated high-throughput quantification of plasma p-tau217 and APOE-e4 for Alzheimer's Disease diagnosis and cognitive decline in a memory cohort (2026). 2026. ↩︎ ↩︎
Zheng et al. Targeted blood proteome profiling using NULISAseq identifies a high-performance biomarker panel for A-beta pathology quantification and staging (2026). 2026. ↩︎
Yeo et al. Visuospatial memory deficit, plasma p-tau217, and A-beta42/A-beta40 ratio enhance sensitivity to identify A-beta PET positivity in individuals with SCD (2026). 2026. ↩︎
Kong et al. 'Diagnostic and prognostic utility of serum beta-synuclein in Alzheimer''s Disease: a longitudinal cohort study (2026)'. 2026. ↩︎
Janelidze et al. 'Diagnostic Value of Serum p-tau217 in Alzheimer''s Disease: Equal to Plasma in Levels and Clinical Utility? (2026)'. 2026. ↩︎
Mavridis et al. Plasma Phosphorylated Tau 217 Cutoffs for Amyloid Pathology and Kidney Function, Body Mass Index, and Anemia (2026). 2026. ↩︎
Rizvi et al. Whole blood gene expression moderates associations between AD biomarkers and cognitive decline in cognitively unimpaired older adults (2026). 2026. ↩︎
Sperling et al. The prognostic value of blood-based p-tau217 levels on progression to clinical impairment (2026). 2026. ↩︎
Jucker et al. Plasma levels of an N-terminal tau fragment predict Alzheimer's and neurodegenerative disease biomarkers in autosomal dominant Alzheimer's Disease (2026). 2026. ↩︎
Cánovas et al. When Does Alzheimer's Disease Start? Plasma Aβ42/40 Assays Show Steep Changes at Aβ-PET Centiloid 15, Mean Age of 66 Years (2026). 2026. ↩︎
Choo et al. Longitudinal subcortical volume changes and their correlations with multiple PET and fluid biomarkers in dominantly inherited Alzheimer's Disease (2026). 2026. ↩︎
Holtzman et al. Analyses of plasma multi-omic data across ancestries identify novel pathways implicated in Alzheimer's Disease (2026). 2026. ↩︎
Honig et al. Biological age acceleration associates with Alzheimer's Disease plasma biomarker levels (2026). 2026. ↩︎ ↩︎
Honig et al. Lysophosphatidylcholines are associated with amyloidosis in early stages of Alzheimer's Disease (2026). 2026. ↩︎ ↩︎
Zetterberg et al. Vascular stiffness predicts plasma markers of neurodegeneration among older African Americans (2026). 2026. ↩︎ ↩︎